Loading…
SBI Pharma Fund
Disclosed for 2 months, Nov 2013 to Dec 2013. This scheme is no longer reporting.
Portfolio value
₹185 Cr
up ₹37.6 Cr vs Nov 2013
- Stocks held
- 15
- down 2 vs Nov 2013
- Top 10 weight
- 90.9%
- of the portfolio in its ten largest
- Cash & debt
- 2.7%
- cash, money market and debt
- Moves this month
- 0 in · 2 out
- added to 10, trimmed 2
SBI Pharma Fund is an active equity fund in the Sectoral / Thematic category from SBI Mutual Fund. In December 2013 it disclosed 15 stocks worth ₹185 Cr, up ₹37.6 Cr from Nov 2013. Its largest positions were Sun Pharmaceutical Industries Limited (24.1%), Dr. Reddy's Laboratories Limited (16.4%), Lupin Limited (11.4%); the ten largest together made up 90.9% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 96.6% of its equity. Cash and debt stood at 2.7%. Compared with Nov 2013 the fund entered 0 new stocks and exited 2.
Against 230 other Sectoral / Thematic funds
Concentration
100%
Top-10 weight is higher than 100% of peers
Breadth
2%
Holds more stocks than 2% of peers
Cash
38%
Holds more cash than 38% of peers
What these mean: concentration · cash
Holdings in December 2013
Download CSVEvery line the fund disclosed, with the change against Nov 2013. Click a column to sort; click a company to see every fund that owns it. New to these? How to read a portfolio.
| Sun Pharmaceutical Industries Limited | 24.07% | down 0.95 pts | ₹44.6 Cr | up ₹7.7 Cr | Added |
| Dr. Reddy's Laboratories Limited | 16.41% | down 0.26 pts | ₹30.4 Cr | up ₹5.8 Cr | Added |
| Lupin Limited | 11.38% | up 0.37 pts | ₹21.1 Cr | up ₹4.8 Cr | Added |
| Cipla Limited | 10.60% | up 5.30 pts | ₹19.6 Cr | up ₹11.8 Cr | Added |
| Glenmark Pharmaceuticals Limited | 6.05% | up 0.10 pts | ₹11.2 Cr | up ₹2.4 Cr | Added |
| IPCA Laboratories Limited | 5.84% | up 0.92 pts | ₹10.8 Cr | up ₹3.6 Cr | Added |
| Divi's Laboratories Limited | 5.61% | down 0.47 pts | ₹10.4 Cr | up ₹1.4 Cr | Added |
| Aurobindo Pharma Limited | 5.30% | up 0.33 pts | ₹9.8 Cr | up ₹2.5 Cr | Added |
| Natco Pharma Limited | 3.05% | down 0.64 pts | ₹5.6 Cr | up ₹20 L | Added |
| Cash, TREPS & receivables | 2.74% | up 0.90 pts | ₹5.1 Cr | up ₹2.4 Cr | Added |
| Indoco Remedies Limited | 2.59% | down 0.03 pts | ₹4.8 Cr | up ₹94 L | Added |
| Hikal Limited | 2.50% | down 0.37 pts | ₹4.6 Cr | up ₹40 L | Added |
| Alembic Pharmaceuticals Limited | 2.27% | up 0.19 pts | ₹4.2 Cr | up ₹1.1 Cr | Added |
| Procter & Gamble Health Limited | 0.91% | down 0.36 pts | ₹1.7 Cr | down ₹20 L | Trimmed |
| SHASUN PHARMACEUTICALS LTD. | 0.39% | down 0.05 pts | ₹72 L | up ₹8 L | Added |
| Strides Pharma Science Limited | 0.29% | down 2.62 pts | ₹54 L | down ₹3.8 Cr | Trimmed |
What changed, Nov 2013 to Dec 2013
New New positions (0)
None.
Exited Exited (2)
- Torrent Pharmaceuticals Limitedwas 2.0% · ₹3 Cr
- Wyeth Ltdwas 0.3% · ₹49 L
Added Biggest additions
- Cipla Limitedup ₹11.8 Cr (+5.30% pts)
- Sun Pharmaceutical Industries Limitedup ₹7.7 Cr (−0.95% pts)
- Dr. Reddy's Laboratories Limitedup ₹5.8 Cr (−0.26% pts)
- Lupin Limited
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
Compared with
Since Nov 2013, the weight rose most in Pharmaceuticals & Biotechnology (+3.1 pts), and fell most in Pharmaceuticals (−3.1 pts).
- Pharmaceuticals & Biotechnology93.6% → 96.6%+3.1 pts
- Pharmaceuticals6.4% → 3.4%−3.1 pts
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
Main sectors’ weights over time
| Sector | Nov 2013 | Dec 2013 |
|---|---|---|
| Pharmaceuticals & Biotechnology | 93.6% | 96.6% |
| Pharmaceuticals | 6.4% | 3.4% |
Allocation in Dec 2013change vs Nov 2013
- Pharmaceuticals & Biotechnology (12)96.6%▲ 3.1 pts
- Pharmaceuticals (3)3.4%▼ 3.1 pts
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal. More on reading cash.
Cash & debt, Dec 2013
2.7%
▲ 0.9 pts vs Nov 2013
- Cash alone
- 2.7%
- cash and net receivables
- A year earlier
- —
- no disclosure
- Last 12 months
- 1.8% – 2.7%
- lowest to highest · record 2.7% in Dec 2013
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.